Backed by proxy firms Glass Lewis and Institutional Shareholder Services (ISS), New York City Pension Funds and a group of institutional investors told EpiPen maker Mylan’s shareholders Monday to air their grievances —in paper form— with the allergy treatment company’s board of directors and its chairman’s pay at Mylan’s June 22 shareholder meeting.